BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $700 | -99.9% | 13,739 | 0.0% | 0.02% | -14.3% |
| Q3 2022 | $740,000 | -28.2% | 13,739 | -14.4% | 0.02% | -22.2% |
| Q2 2022 | $1,031,000 | -22.0% | 16,053 | -5.9% | 0.03% | -10.0% |
| Q1 2022 | $1,322,000 | -14.6% | 17,055 | -5.4% | 0.03% | -9.1% |
| Q4 2021 | $1,548,000 | +3.8% | 18,035 | -2.7% | 0.03% | -5.7% |
| Q3 2021 | $1,491,000 | -7.8% | 18,540 | -7.8% | 0.04% | -7.9% |
| Q2 2021 | $1,618,000 | -1.9% | 20,098 | +2.7% | 0.04% | -9.5% |
| Q1 2021 | $1,650,000 | +12.0% | 19,563 | +6.6% | 0.04% | +5.0% |
| Q4 2020 | $1,473,000 | -0.2% | 18,359 | +0.0% | 0.04% | -11.1% |
| Q3 2020 | $1,476,000 | -6.6% | 18,358 | +0.0% | 0.04% | -15.1% |
| Q2 2020 | $1,580,000 | +25.1% | 18,356 | +18.0% | 0.05% | +8.2% |
| Q1 2020 | $1,263,000 | -2.9% | 15,555 | +0.0% | 0.05% | +19.5% |
| Q4 2019 | $1,301,000 | -5.9% | 15,554 | -1.7% | 0.04% | -12.8% |
| Q3 2019 | $1,383,000 | +10.5% | 15,816 | +3.5% | 0.05% | +9.3% |
| Q2 2019 | $1,252,000 | +0.2% | 15,286 | -0.6% | 0.04% | -2.3% |
| Q1 2019 | $1,250,000 | +22.5% | 15,373 | -0.8% | 0.04% | +10.0% |
| Q4 2018 | $1,020,000 | -8.7% | 15,493 | +6.9% | 0.04% | +5.3% |
| Q3 2018 | $1,117,000 | +2.9% | 14,489 | -1.4% | 0.04% | -5.0% |
| Q2 2018 | $1,085,000 | +13.6% | 14,689 | 0.0% | 0.04% | +11.1% |
| Q1 2018 | $955,000 | -3.1% | 14,689 | -3.7% | 0.04% | +2.9% |
| Q4 2017 | $986,000 | +2.4% | 15,254 | -0.7% | 0.04% | -2.8% |
| Q3 2017 | $963,000 | +3.5% | 15,354 | 0.0% | 0.04% | +2.9% |
| Q2 2017 | $930,000 | +18.3% | 15,354 | +1.3% | 0.04% | +12.9% |
| Q1 2017 | $786,000 | +48.9% | 15,151 | +27.2% | 0.03% | +40.9% |
| Q4 2016 | $528,000 | -6.9% | 11,913 | 0.0% | 0.02% | -8.3% |
| Q3 2016 | $567,000 | +3.8% | 11,913 | -1.4% | 0.02% | +4.3% |
| Q2 2016 | $546,000 | +8.8% | 12,082 | -1.1% | 0.02% | +9.5% |
| Q1 2016 | $502,000 | +13.6% | 12,219 | +5.4% | 0.02% | +10.5% |
| Q4 2015 | $442,000 | +4.0% | 11,597 | -10.4% | 0.02% | 0.0% |
| Q3 2015 | $425,000 | -60.3% | 12,947 | -15.4% | 0.02% | -57.8% |
| Q2 2015 | $1,070,000 | +3.1% | 15,297 | +1.0% | 0.04% | 0.0% |
| Q1 2015 | $1,038,000 | -8.0% | 15,147 | -1.6% | 0.04% | -6.2% |
| Q4 2014 | $1,128,000 | +1.3% | 15,391 | -0.8% | 0.05% | -2.0% |
| Q3 2014 | $1,114,000 | -2.8% | 15,522 | -2.1% | 0.05% | -3.9% |
| Q2 2014 | $1,146,000 | +21.7% | 15,853 | +17.0% | 0.05% | +15.9% |
| Q1 2014 | $942,000 | -0.1% | 13,553 | 0.0% | 0.04% | 0.0% |
| Q4 2013 | $943,000 | +15.3% | 13,553 | +8.9% | 0.04% | +4.8% |
| Q3 2013 | $818,000 | -5.1% | 12,449 | 0.0% | 0.04% | -10.6% |
| Q2 2013 | $862,000 | – | 12,449 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |